Fusion startups have been on a fundraising tear lately, and a young startup, Acceleron Fusion, is joining the pack, having raised $15 million of a targeted $23.7 million round, according to an SEC ...

ACCELERON SOLUTIONS PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the ...

Just months after striking its $11.5 billion deal for Acceleron Pharma, Merck & Co. has telegraphed its plans to cut back at its newly acquired unit. Merck is laying off a clutch of Acceleron staffers ...

- Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL ® (luspatercept-aamt) - - Three clinical abstracts on ...

Merck's blood vessel disorder drug succeeds in late-stage study Merck & Co said on Monday a therapy it gained through the drugmaker's $11.5 billion acquisition of Acceleron Pharma last year met the ...

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its ...

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates ...

Merck & Co.’s agreement to buy Acceleron Pharma Inc. for about $11.5 billion “drastically undervalues” the biotechnology firm, one of its largest investors contends. Avoro Capital, which invests in ...

Sept 30 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday it would buy Acceleron Pharma Inc (XLRN.O), opens new tab for about $11.5 billion, broadening its portfolio beyond aging cancer ...